• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

Opinion
Video

A Friedreich ataxia specialist discusses how the typical clinical presentation of Friedreich's Ataxia includes early onset with symptoms such as ataxia and sensory loss, while also examining the pathophysiology and incidence rate of the condition.

Video content above is prompted by the following:

  • Describe the typical clinical presentation of FA in terms of age of onset, initial symptoms, and life expectancy?
  • Can you summarize the pathophysiology and incidence rate of Friedreich's Ataxia (FA)? 
Related Videos
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Susan Perlman, MD, an expert on Friedreich's ataxia
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Susan Perlman, MD, an expert on Friedreich's ataxia
Related Content
Nurse helping patient use walker | Image credit: LIGHTFIELD STUDIOS – stock.adobe.com

Genotypes May Influence When Patients With DMD Have Loss of Ambulation

October 9th 2024
Article

A study of 555 patients further solidified genotype-phenotype correlations in Duchenne muscular dystrophy (DMD).

Read More

Currently, 4 exon-skipping drugs are FDA approved for DMD: eteplirsen (Exondys 51), golodirsen (Vyondys 53), casimersen (Amondys 45), and viltolarsen (Viltepso) | Image credit: CrazyJuke - stock.adobe.com

WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis

September 26th 2024
Article

In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

Read More

The new results make HERCULES the first and only study to demonstrate reduced CDP in nrSPMS. | Image credit: Juan Gärtner - stock-adobe.com

Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS

September 3rd 2024
Article

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS).

Read More

Balance and gait are both important factors in continued mobility among patients with DMD. | Image credit: OlegKachura - stock.adobe.com

Cycling Training Shows Protective Effects on Gait, Balance in DMD

August 22nd 2024
Article

Both cycling and home-based exercise training helped maintain gait and balance parameters in children with Duchenne muscular dystrophy (DMD), with cycling training also improving antero-posterior balance.

Read More

Results demonstrate correlations between fatigue and walking speed and mobility among patients with multiple sclerosis. | Image credit: kieferpix - stock.adobe.com

Fatigue Linked With Reduced Walking Speed, Mobility in Multiple Sclerosis

August 13th 2024
Article

Study results demonstrated significant correlations between fatigue and reductions in walking speed and mobility among patients with multiple sclerosis.

Read More

Healthy behaviors, especially regular exercise and a healthy diet, were associated with better patient-reported outcomes in multiple sclerosis. | Image credit: Daniel Vincek - stock.adobe.com

Healthy Lifestyle Behaviors Linked to Better MS Outcomes

August 7th 2024
Article

Engaging with healthy lifestyle behaviors, including a healthy diet and physical activity, was associated with better outcomes among patients with multiple sclerosis (MS).

Read More

© 2024 MJH Life Sciences
AJMC®
All rights reserved.